- Large Molecules
- Small Molecules
Sterile Injectables Market size was valued at USD 52.1 million in 2021, growing at a CAGR of 7.2% during the forecast period 2022-2028. Several industry experts noted that the cost of establishing sterile injectable plants is significantly higher viz-a-viz non-sterile manufacturing plants owing to stringent aseptic requirements and complex manufacturing process; this has led to the consolidation of the industry by backward and forward integration. Moreover, competition from low-cost manufacturers, value chain integration coupled with high entry barrier for new players in the sterile injectable market expect impact market growth negatively over the forecast period. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. The sterile injectable market report also includes drug pipeline analysis, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analysed sterile injectable market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities).
Fastest Growing Market
The rising shift of pharmaceutical and biotechnology firms towards the development of medications for chronic diseases such as cancer, diabetes, and cardiovascular and among others have created ample growth opportunities for players in the market. Moreover, biologics have become a larger part of product pipelines of several drug developers, which could affect market growth positively over the forecast period. For instance, there are around 2,500 injectable products are in the developmental stage. Moreover, rising product patent expiries of several blockbusters in recent times expected to propel market growth over the forecast period. For instance, in 2015, Teva Pharmaceutical Industries Ltd. lost the patent for its top-selling multiple sclerosis drug Copaxone.
The sterile injectables market is projected to expand at a CAGR of 7.2% during the forecast period
AbbVie Inc, Amgen Inc, AstraZeneca plc, Baxter International Inc, Eli Lilly and Company
North America is the fastest-growing region for cell therapy market